Results 141 to 150 of about 234,795 (273)

Chronic plaque psoriasis

PAMJ Clinical Medicine, 2022
Trupti Thakre, Sourabh Deshmukh
openaire   +1 more source

The worldwide burden of skin diseases: Lessons from the Global Burden of Disease data

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Skin diseases are a major public health concern worldwide, causing significant personal, economic and social burdens. The Global Burden of Disease (GBD) initiative provides valuable insights but underestimates the burden of skin diseases, emphasizing the urgent need for improved data collection and global collaboration among stakeholders.
Luigi Naldi, Simone Cazzaniga, Carsten Flohr, Marco May Lee, Claire Fuller, Roderick Hay, Esther E. Freeman, Rashmi Sarkar, Ricardo Romiti, Antonio Torrelo, Qianjin Lu, Ncoza Dlova, Visnja Zaborski Breton, Jennifer Austin, Matthias Augustin, Henry Lim, Luca Borradori   +16 more
wiley   +1 more source

Dupilumab‐Induced Psoriasis in a Patient with Bullous Pemphigoid

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nina Matthes, Julian Kött, Finn Abeck, Inga Hansen‐Abeck, Jana Bertels, Nina Booken, Stefan W. Schneider   +6 more
wiley   +1 more source

Cardiac structure and function in psoriasis: A cross‐sectional analysis of the PSOCADIA study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Individuals with well‐treated psoriasis exhibited a higher burden of myocardial dysfunction (GLS < 16%) compared with controls, independent of cardiometabolic comorbidity. The prevalence was similar across psoriasis severity, highlighting the importance of cardiovascular assessment in all patients with psoriasis. Abstract Background Psoriasis is linked
Maria Dons, Morten Sengeløv, Kristoffer Grundtvig Skaarup, Niklas Dyrby Johansen, Mats C. H. Lassen, Sofie Bøgh‐Sørensen, Filip Soeskov Davidovski, Julie Borchsenius, Peter Schnohr, Gorm Boje Jensen, Rasmus Møgelvang, Christoffer V. Nissen, Peter Riis Hansen, Brittany N. Weber, Claus Zachariae, Lone Skov, Tor Biering‐Sørensen   +16 more
wiley   +1 more source

Triple therapy with deucravacitinib, methotrexate, and dexamethasone unsuccessful for refractory lichen planus

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Neda Cramer, Caroline Sophie Jonas, Michael P. Schön, Rotraut Mössner   +3 more
wiley   +1 more source

European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Updated S2k hidradenitis suppurativa (HS) guidelines provide expert consensus on diagnosis, assessment and comorbidities. Expanded substantially since the 2015 version, they reflect rapid growth in HS literature and aim to improve generalist‐level patient care through evidence‐informed, consensus‐based guidance.
G. B. E. Jemec, B. Villumsen, K. R. van Straalen, H. H. van der Zee, S. Valiukevičienė, T. Tzellos, J. C. Szepietowski, A. Szegedi, D. M. L. Saunte, M. Romanelli, H. Raynal, F. Prignano, E. P. Prens, M. Podda, A. Nassif, A. Molina‐Leyva, Ł. Matusiak, A. V. Marzano, B. M. McGrath, A. I. Liakou, B. Kirby, L. Kemény, E. Just, D. Ioannidis, J. R. Ingram, R. E. Hunger, B. Horváth, P. Guillem, Ø. Grimstad, E. J. Giamarellos‐Bourboulis, M. Dolenc‐Voljč, V. Del Marmol, Z. Bukvić Mokos, V. Bettoli, F. Benhadou, F. G. Bechara, C. C. Zouboulis   +36 more
wiley   +1 more source

Potential role of ustekinumab in the treatment of chronic plaque psoriasis

, 2010
Santo Raffaele Mercuri1, Luigi Naldi21Unit&agrave; di Dermatologia, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele, Universit&agrave; Vita-Salute, Milano, Italy; 2Centro Studi GISED, Fondazione per la Ricerca Ospedale Maggiore ...
Santo Raffaele Mercuri, Luigi Naldi
core  

A randomized phase 2 trial of socrodeucitinib in moderate‐to‐severe plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In moderate‐to‐severe plaque psoriasis, socrodeucitinib (6 mg/12 mg) significantly outperformed placebo at week 12: PASI 75 response rates 28.6%/72.1% vs. 7.5%. Meanwhile, socrodeucitinib illustrated a favourable safety and tolerability profile, warranting further study.
Ling Han, Songmei Geng, Yangfeng Ding, Shifa Zhang, Xiaohua Wang, Fengming Hu, Jianguo Li, Chao Ci, Yayu Hu, Rixin Chen, Jianping Zhang, Xiaoyong Zhou, Aijun Chen, Chunlei Zhang, Tiechi Lei, Yanyan Feng, Yu Wang, Zudong Meng, Yan Zhou, Mingkai Ji, Wei Liu, Yunting Wu, Qianying Chen, Siyi Wang, Jinhua Xu   +24 more
wiley   +1 more source

Multi‐omics analyses reveal host–microbe interactions in atopic dermatitis and psoriasis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Atopic dermatitis (AD) and psoriasis (PSO) are chronic inflammatory skin diseases with complex host–microbe interactions. This study analysed skin samples from patients and healthy individuals using integrated microbial and transcriptomic profiling. Both diseases showed disrupted fungal–bacterial interactions and alterations in host immune responses ...
Ying Yang, Peter Olah, Alexander Salava, Jonathan Barker, Antti Lauerma, Björn Andersson, Nanna Fyhrquist, Bernhard Homey, Harri Alenius   +8 more
wiley   +1 more source

Molecular Signature and miRNA Pattern of CD4 + T Lymphocytes in Plaque Psoriasis. [PDF]

Clin Rev Allergy Immunol
Dubna Y, Nazimek K.
europepmc   +1 more source